Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Deoxycorticosterone acetate** is a synthetic **mineralocorticoid** steroid hormone ester, chemically identified as the C21 acetate ester of 11-deoxycorticosterone. It acts as a prodrug, releasing active deoxycorticosterone after intramuscular injection. Deoxycorticosterone acetate functions as a potent mineralocorticoid, primarily *increasing renal tubular sodium reabsorption* and promoting potassium excretion, mimicking the biological effects of aldosterone. Its mechanism involves binding mineralocorticoid receptors in the cytoplasm of renal tubular cells, leading to gene transcription and upregulation of protein synthesis responsible for electrolyte homeostasis. It has historically been used in adrenal insufficiency (Addison’s disease), especially before the availability of fludrocortisone, but is primarily used now as an animal pharmaceutical for replacement therapy in veterinary medicine[1][2][3][5]. In research, it is widely used to induce hypertension in laboratory animal models[4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deoxycorticosterone acetate.